Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.06
CPHD's Cash to Debt is ranked higher than
62% of the 295 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. CPHD: 1.06 )
CPHD' s 10-Year Cash to Debt Range
Min: 0.88   Max: 11006.5
Current: 1.06

0.88
11006.5
Equity to Asset 0.45
CPHD's Equity to Asset is ranked higher than
59% of the 287 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. CPHD: 0.45 )
CPHD' s 10-Year Equity to Asset Range
Min: 0.32   Max: 0.9
Current: 0.45

0.32
0.9
F-Score: 4
Z-Score: 6.24
M-Score: -2.89
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -4.67
CPHD's Operating margin (%) is ranked higher than
68% of the 289 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.79 vs. CPHD: -4.67 )
CPHD' s 10-Year Operating margin (%) Range
Min: -233.91   Max: 1.37
Current: -4.67

-233.91
1.37
Net-margin (%) -8.05
CPHD's Net-margin (%) is ranked higher than
67% of the 289 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.80 vs. CPHD: -8.05 )
CPHD' s 10-Year Net-margin (%) Range
Min: -220.28   Max: 0.95
Current: -8.05

-220.28
0.95
ROE (%) -11.10
CPHD's ROE (%) is ranked higher than
67% of the 273 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.68 vs. CPHD: -11.10 )
CPHD' s 10-Year ROE (%) Range
Min: -85.87   Max: 1.44
Current: -11.1

-85.87
1.44
ROA (%) -5.16
CPHD's ROA (%) is ranked higher than
68% of the 299 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.00 vs. CPHD: -5.16 )
CPHD' s 10-Year ROA (%) Range
Min: -61.04   Max: 1.04
Current: -5.16

-61.04
1.04
ROC (Joel Greenblatt) (%) -11.20
CPHD's ROC (Joel Greenblatt) (%) is ranked higher than
70% of the 298 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.49 vs. CPHD: -11.20 )
CPHD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -619.62   Max: 6.69
Current: -11.2

-619.62
6.69
Revenue Growth (3Y)(%) 17.30
CPHD's Revenue Growth (3Y)(%) is ranked higher than
92% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.20 vs. CPHD: 17.30 )
CPHD' s 10-Year Revenue Growth (3Y)(%) Range
Min: -15.4   Max: 56.7
Current: 17.3

-15.4
56.7
» CPHD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

CPHD Guru Trades in Q1 2014

PRIMECAP Management 2,270,400 sh (+4.19%)
Ron Baron 889,830 sh (+0.83%)
Columbia Wanger 8,360,000 sh (unchged)
Mario Gabelli 235,500 sh (-1.26%)
Columbia Wanger 7,467,000 sh (-10.68%)
» More
Q2 2014

CPHD Guru Trades in Q2 2014

Ron Baron 902,506 sh (+1.42%)
Columbia Wanger 7,467,000 sh (unchged)
Mario Gabelli 235,000 sh (-0.21%)
PRIMECAP Management 2,255,200 sh (-0.67%)
» More
Q3 2014

CPHD Guru Trades in Q3 2014

Columbia Wanger 7,745,200 sh (+3.73%)
Ron Baron 913,196 sh (+1.18%)
PRIMECAP Management 2,255,200 sh (unchged)
Mario Gabelli 234,500 sh (-0.21%)
» More
Q4 2014

CPHD Guru Trades in Q4 2014

PRIMECAP Management 2,310,100 sh (+2.43%)
Mario Gabelli 233,500 sh (-0.43%)
Ron Baron 884,701 sh (-3.12%)
Columbia Wanger 7,203,300 sh (-7.00%)
» More
» Details

Insider Trades

Latest Guru Trades with CPHD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 217.39
CPHD's Forward P/E is ranked higher than
68% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. CPHD: 217.39 )
N/A
P/B 11.47
CPHD's P/B is ranked lower than
58% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.70 vs. CPHD: 11.47 )
CPHD' s 10-Year P/B Range
Min: 2.25   Max: 14.01
Current: 11.47

2.25
14.01
P/S 8.79
CPHD's P/S is ranked lower than
59% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.43 vs. CPHD: 8.79 )
CPHD' s 10-Year P/S Range
Min: 1.76   Max: 14.01
Current: 8.79

1.76
14.01
POCF 453.62
CPHD's POCF is ranked higher than
73% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. CPHD: 453.62 )
CPHD' s 10-Year POCF Range
Min: 45.31   Max: 1642.33
Current: 453.62

45.31
1642.33
Current Ratio 3.77
CPHD's Current Ratio is ranked higher than
80% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.52 vs. CPHD: 3.77 )
CPHD' s 10-Year Current Ratio Range
Min: 1.36   Max: 14.11
Current: 3.77

1.36
14.11
Quick Ratio 2.80
CPHD's Quick Ratio is ranked higher than
76% of the 295 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. CPHD: 2.80 )
CPHD' s 10-Year Quick Ratio Range
Min: 0.97   Max: 13.54
Current: 2.8

0.97
13.54
Days Inventory 198.16
CPHD's Days Inventory is ranked higher than
64% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 138.68 vs. CPHD: 198.16 )
CPHD' s 10-Year Days Inventory Range
Min: 57.37   Max: 629.87
Current: 198.16

57.37
629.87
Days Sales Outstanding 55.00
CPHD's Days Sales Outstanding is ranked higher than
83% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.03 vs. CPHD: 55.00 )
CPHD' s 10-Year Days Sales Outstanding Range
Min: 40.78   Max: 124.41
Current: 55

40.78
124.41

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 52.18
CPHD's Price/Net Current Asset Value is ranked higher than
68% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. CPHD: 52.18 )
CPHD' s 10-Year Price/Net Current Asset Value Range
Min: 4.24   Max: 47.91
Current: 52.18

4.24
47.91
Price/Tangible Book 14.04
CPHD's Price/Tangible Book is ranked higher than
54% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.60 vs. CPHD: 14.04 )
CPHD' s 10-Year Price/Tangible Book Range
Min: 2.1   Max: 20.68
Current: 14.04

2.1
20.68
Price/DCF (Projected) 38.05
CPHD's Price/DCF (Projected) is ranked higher than
75% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. CPHD: 38.05 )
CPHD' s 10-Year Price/DCF (Projected) Range
Min: 24.01   Max: 58.32
Current: 38.05

24.01
58.32
Price/Median PS Value 1.29
CPHD's Price/Median PS Value is ranked higher than
71% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. CPHD: 1.29 )
CPHD' s 10-Year Price/Median PS Value Range
Min: 0.51   Max: 3.17
Current: 1.29

0.51
3.17
Earnings Yield (Greenblatt) -0.80
CPHD's Earnings Yield (Greenblatt) is ranked higher than
65% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. CPHD: -0.80 )
CPHD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 0.4
Current: -0.8

0.1
0.4

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:XEP.Germany,
Cepheid was incorporated in the State of California on March 4, 1996. The Company is a molecular diagnostics company that develops, manufactures and markets integrated systems for testing in the clinical market, as well as for application in its non-clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's product portfolio consists of tests, reagents and systems for the clinical and non-clinical markets. The Company's two systems are the GeneXpert and SmartCycler. The GeneXpert system, offers services in the clinical market, integrates sample preparation in addition to DNA amplification and detection. The GeneXpert system is designed for user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals and doctors' offices. The SmartCycler system integrates DNA amplification and detection to allow rapid analysis of a sample. Company faces competition from a number of companies that offer products to its target markets. Company has patents covering technologies of its own and has licensed technologies from others. In addition to patents, it rely on a combination of trade secrets, copyright and trademark laws, nondisclosure agreements, licenses and other contractual provisions and technical measures to maintain and develop its competitive position with respect to intellectual property. In the Clinical market, its products are regulated as medical device products by the FDA and comparable agencies in other countries. For the Non-Clinical market, all of its products are being produced under ISO 13485 and Quality System Regulations.
» More Articles for NAS:CPHD

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: SeaCube, Hasbro, Cepheid, Honeywell Apr 28 2013 
Weekly CFO Sales Highlight: CLB, CPHD, ALXN, RDEA, BCR Jul 31 2011 
CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares Feb 28 2011 
CEPHEID Reports Operating Results (10-K) Feb 24 2011 
CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares Feb 15 2011 
CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares Feb 08 2011 
CEPHEID (CPHD) SVP, CFO Andrew Miller sells 10,000 Shares Dec 09 2010 
CEPHEID Reports Operating Results (10-Q) Nov 04 2010 
CEPHEID Reports Operating Results (10-Q) Aug 04 2010 
CEPHEID Reports Operating Results (10-Q) May 04 2010 

More From Our Partners
3 Hale & Hearty Stocks for World Health Day - Analyst Blog Apr 7 2015 - ZACKS

More From Other Websites
Biz Break: The 2015 SV150: Apple in command, Wall Street has demands Apr 24 2015
Cepheid (CPHD) Turns it Around with Q1 Earnings; Guides Up - Analyst Blog Apr 24 2015
Cepheid tops Street 1Q forecasts Apr 23 2015
Cepheid tops Street 1Q forecasts Apr 23 2015
Cepheid Earnings Call scheduled for 5:00 pm ET today Apr 23 2015
Cepheid Reports 2015 First Quarter Results Apr 23 2015
CEPHEID Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and... Apr 23 2015
Cepheid Reports 2015 First Quarter Results Apr 23 2015
Q1 2015 Cepheid Earnings Release - After Market Close Apr 23 2015
Intuitive Surgical Q1 Earnings, Revenues Miss; Shares Fall - Analyst Blog Apr 22 2015
Cepheid's (CPHD) Xpert HIV-1 Qual Test Gets CE-IVD Mark - Analyst Blog Apr 20 2015
Cepheid and FIND Announce European Approval of Xpert HIV-1 Qual Apr 16 2015
Cepheid and FIND Announce European Approval of Xpert HIV-1 Qual Apr 16 2015
Cepheid Announces European Approval of Xpert HCV Viral Load Apr 15 2015
Cepheid Announces European Approval of Xpert HCV Viral Load Apr 15 2015
Cepheid Welcomes Executive Vice President And Chief Financial Officer Apr 07 2015
Cepheid Schedules 2015 First Quarter Results Announcement And Webcast Apr 07 2015
CEPHEID Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or... Apr 07 2015
Cepheid Welcomes Executive Vice President And Chief Financial Officer Apr 07 2015
Cepheid Schedules 2015 First Quarter Results Announcement And Webcast Apr 07 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK